Tag: Alder Biopharmaceuticals

September 22, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Lexicon Soars

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
September 16, 2019

Lundbeck to Buy Alder BioPharma in US$2 Billion Deal

Lundbeck will add Alder BioPharma's potential blockbuster migraine treatment, eptinezumab, to its pipeline ahead of patent expirations.
May 6, 2019

Alder BioPharmaceuticals Presents New Data from Clinical Trials

Alder BioPharmaceuticals (NASDAQ:ALDR) has released new data showing consistency of early migraine prevention benefit in four clinical trials with eptinezumab....
October 23, 2018

Alder BioPharmaceuticals Announces Positive Results From Pharmacokinetic Comparability Study for Eptinezumab

Alder Biopharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced positive...
May 9, 2018

Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results

Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today provided a...
April 25, 2018

Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine

Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new...
April 24, 2018

Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine

Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new...